Duloxetine
Product Images NDC 50436-0387

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50436-0387). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Delayed-release Capsules (Duloxetinecapsul Figure 01)

Chemical structure of duloxetine hydrochloride showing its molecular framework with a thiophene ring, naphthalene group, and amine hydrochloride moiety.*

FDA Label Image

Duloxetine Delayed-release Capsules (Duloxetinecapsul Figure 02)

A Kaplan-Meier curve graph depicting the proportion of patients with relapse over time from randomization in days. The chart compares two treatments, Placebo (dashed line) and Duloxetine (solid line), showing relapse rates over nearly 200 days.*

FDA Label Image

Duloxetine Delayed-release Capsules (Duloxetinecapsul Figure 03)

A Kaplan-Meier plot showing the proportion of patients who relapsed over time in days from randomization. The plot compares two treatment groups labeled as Placebo and Duloxetine, with Duloxetine having a lower proportion of relapse over time than Placebo.*

FDA Label Image

Duloxetine Delayed-release Capsules (Duloxetinecapsul Figure 04)

A line graph showing the percentage of patients improved in pain from baseline, with percent improvement on the x-axis and percentage of patients improved on the y-axis. Four lines represent different groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, illustrating their respective pain improvement profiles.*

FDA Label Image

Duloxetine Delayed-release Capsules (Duloxetinecapsul Figure 05)

Line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The y-axis represents percentage of patients improved, while the x-axis represents percent improvement in pain from baseline.*

FDA Label Image

Duloxetine Delayed-release Capsules (Duloxetinecapsul Figure 06)

A line graph comparing percentage of patients improved in pain from baseline between placebo and Duloxetine 60/120 mg once daily. The x-axis shows percent improvement in pain from baseline, while the y-axis shows percentage of patients improved. Two data series are plotted, with Duloxetine consistently showing higher patient improvement percentages across improvement thresholds.*

FDA Label Image

Duloxetine Delayed-release Capsules (Duloxetinecapsul Figure 07)

A line chart comparing the percentage of patients improved between a placebo group and a DLX 60 mg once daily group across different levels of percent improvement in pain from baseline (BOCF). The x-axis shows percent improvement in pain from 0% to 100%, and the y-axis shows the percentage of patients improved, ranging from 0% to 100%. DLX 60 mg once daily shows a generally higher percentage of patient improvement across all pain improvement percentages compared to placebo.*

FDA Label Image

Duloxetine Delayed-release Capsules (Duloxetinecapsul Figure 08)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine (DLX 60/120 mg once daily) and placebo groups. The x-axis shows percent improvement in pain ranging from 0% to 100%, and the y-axis shows the percentage of patients improved, ranging from 0% to 100%. Duloxetine shows a higher percentage of patients improved at each level of pain improvement compared to placebo.*

FDA Label Image

Label Image (Lbl504360387)

Duloxetine Hydrochloride delayed-release capsules 60 mg in a bottle containing 30 capsules. The label includes manufacturer information, Cadila Healthcare Ltd, Ahmedabad, India, with placeholder lot and expiration dates. It states dosage strength, storage instructions, and a warning to keep out of reach of children. The label also includes a barcode and prescription-only designation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.